Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton-beam irradiation plus intravitreal conbercept for refractory or recurrent polypoidal choroidal vasculopathy
ChiCTR2000038987Phase 3Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jan 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of conbercept in polypoidal choroidal vasculopathy (PCV), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Best-corrected visual acuity (BCVA) and Central foveal retinal thickness (CMT). Started Jan 2019; status: recruiting.
02
Drugs
conbercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on ChiCTR2000038987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038987.